Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide
Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide
复制标题
冷等离子体放电管增强替莫唑胺的抗肿瘤功效
DOI：
10.1021/acsabm.2c00018
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Keidar, Michael
中科院分区：
文献类型：
--
作者：
Yao, Xiaoliang;Yan, Dayun;Lin, Li;Sherman, Jonathan H.;Peters, Katherine B.;Keir, Stephen T.;Keidar, Michael
胶质母细胞瘤（GBM）是一种致命的人类脑肿瘤，生存率低。替莫唑胺（TMZ）已被广泛用于GBM治疗，但有明显的副作用。冷等离子体是在室温附近产生的电离气体。在这里，我们证明了增强TMZ的治疗效果，通过使用冷等离子体源的基础上非平衡等离子体在一个密封的玻璃管，命名为径向冷等离子体放电管（PDT）。光动力疗法仅通过其电磁辐射而不是血浆中的任何化学因素来影响胶质母细胞瘤细胞的功能。与正常星形胶质细胞系hTERT/E6/E7相比，PDT在一定程度上选择性地增强TMZ对两种典型胶质母细胞瘤细胞系U87 MG和A172的细胞毒性。此外，在患者来源的异种移植模型的基础上，我们的初步体内研究表明，与对照组相比，肿瘤屏障小鼠的平均存活天数大幅改善超过100%。PDT不仅不依赖于持续的氦气供应，而且能够抵抗环境变化的干扰。因此，PDT是一种稳定且低成本的冷大气等离子体源。简而言之，这项研究是第一个证明PDT作为一种非侵入性和便携式方式在GBM治疗中有前途的应用。
Glioblastoma (GBM) is a fatal human brain tumor with a low survival rate. Temozolomide (TMZ) has been widely used in GBM therapy with noticeable side effects. Cold plasma is an ionized gas that is generated near room temperature. Here, we demonstrated the enhancement therapeutic efficacy of TMZ via using a cold plasma source based on nonequilibrium plasma in a sealed glass tube, named a radial cold plasma discharge tube (PDT). The PDT affected glioblastoma cells’ function just by its electromagnetic (EM) emission rather than any chemical factors in the plasma. The PDT selectively increased the cytotoxicity of TMZ on two typical glioblastoma cell lines, U87MG and A172, compared with normal astrocyte cell line hTERT/E6/E7 to some extent. Furthermore, on the basis of a patient-derived xenograft model, our preliminary in vivo studies demonstrated the drastically improved mean survival days of the tumor-barrier mice by more than 100% compared to control. The PDT is not only independent of continuous helium supply but is also capable of resisting the interference of environmental changes. Thus, the PDT was a stable and low-cost cold atmospheric plasma source. In short, this study is the first to demonstrate the promising application of PDTs in GBM therapy as a noninvasive and portable modality.